Positive Surgical Margins in RCC More Common Among African Americans
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients.
Second-Line Therapy Options in Metastatic Renal Cell Carcinoma
This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.
First-Line Treatment of Metastatic Renal Cell Carcinoma
This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2.
Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab.
Savolitinib Active in MET-Driven Advanced Papillary RCC
A phase II study has shown that savolitinib is active in a subgroup of patients with papillary renal cell carcinoma with gene amplification or mutations in the MET pathway.
Physical Inactivity Linked to Kidney, Bladder Cancers
Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers.
Could SBRT Have Role in Metastatic Kidney Cancer?
This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma.
Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial
This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.
Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.